PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Tofacitinib - Rheumatoid arthritis
PAD Profile : Tofacitinib - Rheumatoid arthritis Important
Keywords :
RA, Biologic, NICE, immunosuppressant, DMARD, bDmard, Disease modulating, Rheumatology, cytokine modulator, Protein Kinase inhibitor, Jak inhibitor, Janus Kinase
Brand Names Include :
Xeljanz
Important Information :
Severe disease only
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Abatacept
- Certolizumab pegol
- Etanercept
- Golimumab
- Penicillamine
- Rituximab
- Tocilizumab
- Adalimumab
- Sodium aurothiomalate
- Infliximab
- Baricitinib
- Sarilumab
- Filgotinib
- Upadacitinib
Other Indications
Additional Documents
Type
Document
Review Date
Policy Statement
Tofacitinib for moderate to severe Rheumatoid Arthritis - Policy Statement PCN 298-2017 - December 2
Evidence Review
Committee Recommendations
Date
Committee Name
Narrative
03 April 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated rheumatoid arthritis pathway.
02 December 2020
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Rheumatoid Arthritis High Cost DMARDs Drug Treatment Pathway.
The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines. The agreed process and associated documentation is saved here https://surreyccg.res-systems.net/PAD/Search/DrugConditionProfile/6442
18 December 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends tofactinib as a treatment option for the treatment of moderate to severe Rheumatoid Arthritis in line with NICE TA480.
Prescribing will be by hospital specialists only, in line with NICE TA480 using Blueteq initiation and continuation forms. Tofacitinib will be considered RED on the traffic light system.
Associated BNF Codes
10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs